CareDx is trying to make transplant care more personal and proactive, using blood tests and software that help doctors spot rejection earlier and keep patients monitored at home. The big question is whether better clinical proof and deeper connections into hospital systems can power faster growth, even as insurers, regulators, and large hospital groups push back on pricing and testing rules.Read more
CareDx rides a rising wave of organ transplants by selling tests that help doctors track patients after surgery, while pushing into software and AI tools that could make its services easier to use and easier to get covered by insurers. But the same insurers and regulators that help unlock growth could also squeeze payments or limit how often tests are used, putting future profits at risk.Read more
CareDx rides growing demand for transplant testing and easier-to-use digital tools, but new Medicare payment rules could make it much harder to charge premium prices. The bigger question is whether policy shifts, tougher payers, and rising competition start squeezing profits just as the business tries to scale.Read more
No trending discussion available.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
